Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 12/20 | 0.74 |
| ▸ | CA2 | P00918 | 12/20 | 0.74 |
| ▸ | CA9 | Q16790 | 10/20 | 0.74 |
| ▸ | CA12 | O43570 | 4/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | PKM | P14618 | 1/20 | 0.72 |
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3410287 | 0.88 | CA1 (0.77) | CA1CA2CA9CA12MAPT | |
| SCHEMBL18955311 | 0.87 | CA1 (0.64) | CA1CA2CA9CA12MAPT | |
| SCHEMBL1395590 | 0.85 | CA1 (1.00) | CA1CA2CA9CA12MAPT | |
| SCHEMBL7615242 | 0.85 | PTPN7 (1.00) | CA1CA2CA9CA12PTPN7 | |
| SCHEMBL3408263 | 0.84 | CA1 (0.59) | CA1CA2CA9CA12MAPT | |
| SCHEMBL4522845 | 0.83 | CA1 (0.64) | CA1CA2CA9CA12MAPT | |
| SCHEMBL16771334 | 0.82 | CA1 (0.62) | CA1CA2CA9CA12MAPT | |
| SCHEMBL27747721 | 0.81 | CA1 (0.76) | CA1CA2CA9CA12MAPT | |
| SCHEMBL13764406 | 0.79 | MEN1 (0.76) | CA1CA2CA9CA12MAPT | |
| SCHEMBL6301527 | 0.79 | MAPT (0.58) | CA1CA2CA9CA12MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877970-B2 | Inhibitors of carbonic anhydrase IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20090175794-A1 | INHIBITORS OF CARBONIC ANHYDRASE IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
| EP-0863022-B1 | Thermally sensitive recording medium | JUJO PAPER CO LTD (JP) | 2002-09-18 | — | — | EP | disclosed |
| US-6028030-A | CONTAINING AN IMAGE PRESERVATIVE/STABILIZER POLYUREA IN THE THERMAL COLOR DEVELOPING LAYER CONTAINING DYE PRECURSOR | NIPPON PAPER INDUSTRIE CO., LTD. (JP) | 2000-02-22 | — | — | US | disclosed |
| EP-0863022-A1 | Thermally sensitive recording medium | NIPPON PAPER INDUSTRIES CO., LTD. (JP) | 1998-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175794-A1 | INHIBITORS OF CARBONIC ANHYDRASE IX | CA9, CA12, CA1 | CA1 3/4885CA2 7/4885CA9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.